214 results on '"Kawasaki, Tomihisa"'
Search Results
2. Darexaban: Anticoagulant effects in mice and human plasma in vitro, antithrombotic effects in thrombosis and bleeding models in mice and effects of anti-inhibitor coagulant complex and recombinant factor VIIa
3. Additive antithrombotic effect of ASP6537, a selective cyclooxygenase (COX)-1 inhibitor, in combination with clopidogrel in guinea pigs
4. Pharmacological profile of AS1670542, a novel orally-active human thrombopoietin receptor agonist
5. Studies to Use Fission Neutrons in BNCT for Deeper Tumor Lesion
6. Prodrug-based design, synthesis, and biological evaluation of N-benzenesulfonylpiperidine derivatives as novel, orally active factor Xa inhibitors
7. Design, synthesis and biological activity of selective and orally available TF/FVIIa complex inhibitors containing non-amidine P1 ligands
8. Antithrombotic and anticoagulant effects of direct factor Xa inhibitor darexaban in rat and rabbit models of venous thrombosis
9. Potent and selective TF/FVIIa inhibitors containing a neutral P1 ligand
10. Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor
11. AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist
12. Synthesis and biological activity of novel 1,2-disubstituted benzene derivatives as factor Xa inhibitors
13. Pharmacological Action of and Clinical Experience with Pamiteplase, a Novel, Modified, Tissue-Type Plasminogen Activator
14. Biological properties of a specific Gαq/11 inhibitor, YM-254890, on platelet functions and thrombus formation under high-shear stress
15. Effect of YM-254890, a specific Gαq/11 inhibitor, on experimental peripheral arterial disease in rats
16. Orally active factor Xa inhibitor: synthesis and biological activity of masked amidines as prodrugs of novel 1,4-diazepane derivatives
17. YM-254890 analogues, novel cyclic depsipeptides with Gα q/11 inhibitory activity from Chromobacterium sp. QS3666
18. Synthesis and biological activity of novel 1,4-diazepane derivatives as factor Xa inhibitor with potent anticoagulant and antithrombotic activity
19. Structure of YM-254890, a Novel G q/11 Inhibitor from Chromobacterium sp. QS3666
20. Design, synthesis and biological activity of YM-60828 derivatives. Part 2: potent and orally-bioavailable factor Xa inhibitors based on benzothiadiazine-4-one template
21. Design, synthesis and biological activity of YM-60828 derivatives: potent and orally-Bioavailable factor Xa inhibitors based on naphthoanilide and naphthalensulfonanilide templates
22. The Discovery of YM-60828: A Potent, Selective and Orally-Bioavailable Factor Xa Inhibitor
23. Pharmacological properties of YM-57029, a novel platelet glycoprotein IIb/IIIa antagonist
24. Impaired high-shear-stress-induced platelet aggregation in patients with chronic renal failure undergoing haemodialysis
25. Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysis during acute arterial thrombosis in mice
26. Inhibitory effects of ASP6537, a selective cyclooxygenase-1 inhibitor, on thrombosis and neointima formation in rats
27. Discovery of N-[2-Hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (Darexaban, YM150) as a Potent and Orally Available Factor Xa Inhibitor
28. AKR-501 (YM477) in combination with thrombopoietin enhances human megakaryocytopoiesis
29. Effects of Direct Factor Xa Inhibitor, YM150, on Clot Formation and Clot Lysis In Vitro Compared with Other Anticoagulants.
30. Comparison of YM150, an Oral, Direct Factor Xa Inhibitor, with Other Antithrombotic Agents in Rodent Venous and Arterial Thrombosis Models.
31. Experimental Model of Lower Limb Ischemia in Rats and the Effect of YM466, an Oral Direct Factor Xa Inhibitor
32. Biochemical and Pharmacological Profiles of YM150, an Oral Direct Factor Xa Inhibitor.
33. Biological properties of a specific Gαq/11inhibitor, YM-254890, on platelet functions and thrombus formation under high-shear stress
34. Pharmacological properties of a specific Gq/11 inhibitor, YM-254890
35. YM477, a Novel Orally-Active Thrombopoietin Receptor Agonist.
36. Pharmacological properties of YM-254890, a specific Gαq/11 inhibitor, on thrombosis and neointima formation in mice
37. A Novel Gαq/11-selective Inhibitor
38. YM-254890 analogues, novel cyclic depsipeptides with Gαq/11 inhibitory activity from Chromobacterium sp. QS3666
39. Combined effects of a factor Xa inhibitor YM466 and a GPIIb/IIIa antagonist YM128 on thrombosis and neointima formation in mice
40. Structure of YM‐254890, a Novel Gq/11 Inhibitor from Chromobacterium sp. QS3666.
41. Antithrombotic effects of YM466, a synthesized direct inhibitor of factor Xa, in an arterio‐venous shunt thrombosis model in squirrel monkeys
42. Antithrombotic and thrombolytic efficacy of YM-254890, a Gq/11 inhibitor, in a rat model of arterial thrombosis
43. YM-254890, a Novel Platelet Aggregation Inhibitor Produced by Chromobacterium sp. QS3666
44. Pharmacodynamics and pharmacokinetics of YM128, a GPIIb/IIIa antagonist prodrug
45. Comparative Studies of a Humanized Anti-glycoprotein IIb/IIIa Monoclonal Antibody, YM337, and Abciximab on in Vitro Antiplatelet Effect and Binding Properties.
46. Mouse Carotid Artery Ligation Induces Platelet-Leukocyte–Dependent Luminal Fibrin, Required for Neointima Development
47. The High Molecular Mass, Glycoprotein Ib-Binding Protein Flavocetin-A Induces Only Small Platelet Aggregates in Vitro
48. Research and Development of Novel Anti-thrombotic Agents. New anticoagulants.
49. YM337, A platelet glycoprotein IIb/IIIa antagonist, lessens photochemically-induced ischemic brain damage in monkeys
50. A New Animal Model of Thrombophilia Confirms that High Plasma Factor VIII Levels Are Thrombogenic
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.